| Literature DB >> 30127296 |
Csaba Bús1, Norbert Kúsz2, Gusztáv Jakab3, Seyyed Ashkan Senobar Tahaei4, István Zupkó5,6, Valéria Endrész7, Anita Bogdanov8, Katalin Burián9, Boglárka Csupor-Löffler10, Judit Hohmann11,12, Andrea Vasas13.
Abstract
Juncaceae species are rich sources of phenanthrenes. The present study has focused on the isolation and structure determination of biologically active components from Juncus compressus. Eleven compounds (nine phenanthrenes and two flavonoids) have been isolated from the plant by the combination of different chromatographic methods. Two compounds (compressins A (Compound 1) and B (Compound 2)) are novel natural products, while seven phenanthrenes (effusol (Compound 3), effususol (Compound 4), juncusol (Compound 5), 2-hydroxy-1-methyl-4-oxymethylene-5-vinyl-9,10-dihydrophenanthrene (Compound 6), 7-hydroxy-1-methyl-2-methoxy-5-vinyl-9,10-dihydrophenanthrene (Compound 7), effususin A (Compound 8), and dehydroeffusol (Compound 9)), and two flavonoids (apigenin (Compound 10) and luteolin (Compound 11) were isolated for the first time from the plant. Compressin B (Compound 2) is a dimeric phenanthrene, in which two juncusol monomers (Compound 5) are connecting through their C-3 atoms. The structure elucidation of the isolated compounds was carried out using 1D, 2D NMR spectroscopic methods and HR-MS measurements. In vitro investigation of the antiproliferative effect of the phenanthrenes on two cervical (HeLa and SiHa) and an ovarian human tumor cell line (A2780) revealed that compounds have remarkable antiproliferative activity, mainly on the HeLa cell line. Moreover, juncusol (Compound 5) proved to possess significant antiviral activity against the herpes simplex 2 virus (HSV-2).Entities:
Keywords: Juncus compressus; anti-HSV-2; antiproliferative; flavonoid; phenanthrene
Mesh:
Substances:
Year: 2018 PMID: 30127296 PMCID: PMC6222307 DOI: 10.3390/molecules23082085
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of phenanthrenes (Compounds 1–9) isolated from J. compressus.
NMR spectroscopic data for compressin A (Compound 1) (500 MHz (1H), 125 MHz (13C), δ in ppm, CDCl3).
| Position | δH ( | δC, Type | HMBC (H→C) |
|---|---|---|---|
| 1 | 122.7, C | ||
| 1a | 139.5, C | ||
| 2 | 156.2, C | ||
| 3 | 6.71, d (8.6) | 106.9, CH | 1, 2, 4a |
| 4 | 7.62, d (8.6) | 128.3, CH | 1a, 2, 5a |
| 4a | 127.5, C | ||
| 5 | 137.1, C | ||
| 5a | 127.6, C | ||
| 6 | 120.6, C | ||
| 7 | 152.5, C | ||
| 8 | 6.67, s | 113.2, CH | 5a, 6, 7, 9 |
| 8a | 137.9, C | ||
| 9 | 2.64, m (2H) | 30.5, CH2 | 1a, 5a, 8, 8a |
| 10 | 2.70, m (2H) | 25.9, CH2 | 1, 1a, 4a, 8a |
| 11 | 2.22, s | 11.9, CH3 | 1, 1a, 2 |
| 12 | 6.78, dd (17.9, 11.4) | 137.8, CH | 5, 5a, 6 |
| 13 | 5.52, d (11.4) | 119.8, CH2 | |
| 14 | 2.29, s | 13.4, CH3 | 5, 6, 7 |
| OCH3 | 3.85, s | 55.7, CH3 | 2 |
Figure 2Diagnostic COSY (▬) and HMBC (H→C) correlations of Compound 1.
NMR spectroscopic data for compressin B (Compound 2) (500 MHz (1H), 125 MHz (13C), δ in ppm, CDCl3).
| Position | δH ( | δC, Type | HMBC (H→C) |
|---|---|---|---|
| 1, 1′ | 122.0, C | ||
| 1a, 1a′ | 138.6, C | ||
| 2, 2′ | 147.6, C | ||
| 3, 3′ | 116.4, C | ||
| 4, 4′ | 7.66, s | 127.3, CH | 1a, 1a′, 2, 2′, 3, 3′, 5a, 5a′ |
| 4a, 4a′ | 128.1, C | ||
| 5, 5′ | 137.8, C | ||
| 5a, 5a′ | 126.3, C | ||
| 6, 6′ | 120.7, C | ||
| 7, 7′ | 152.3, C | ||
| 8, 8′ | 6.66, s | 113.2, CH | 5a, 5a′, 6, 6′, 7, 7′, 9, 9′ |
| 8a, 8a′ | 137.2, C | ||
| 9, 9′ | 2.62, m | 30.2, CH2 | 1a, 1a′, 5a 5a′, 8, 8′, 8a, 8a′, 10, 10′ |
| 10, 10′ | 2.67, m | 25.6, CH2 | 1, 1′, 1a, 1a′, 4a, 4a′, 8a, 8a′, 9, 9′ |
| 11, 11′ | 2.28, s | 12.6, CH3 | 1, 1′, 1a, 1a′, 2, 2′ |
| 12, 12′ | 6.77, dd (18.0, 11.4) | 137.1, CH | 13, 13′ |
| 13, 13′ | 5.57, dd (11.4, 1.7) | 120.5, CH2 | 12, 12′ |
| 14, 14′ | 2.27, s | 13.3, CH3 | 5, 5′, 6, 6′, 7, 7′ |
| 2-OH, 2′-OH | 5.56, s | 1, 1′, 2, 2′, 3, 3′ | |
| 7-OH, 7-OH’ | 4.73, s |
Figure 3Diagnostic COSY (▬) and HMBC (H→C) correlations of Compound 2.
Figure 4NOESY correlations of Compound 2.
Antiproliferative effects of the isolated phenanthrenes (1–9) on human cancer cell lines.
| Compound | Concentration (μM) | Growth Inhibition (%) ± SEM | ||
|---|---|---|---|---|
| HeLa | SiHa | A2780 | ||
|
| 10 | 41.67 ± 1.10 | – * | 47.64 ± 1.58 |
| 30 | 93.73 ± 0.36 | 38.56 ± 0.78 | 73.00 ± 0.47 | |
| 11.27 | 13.19 | |||
|
| 10 | 92.03 ± 0.44 | – | – |
| 30 | 92.38 ± 0.15 | 32.82 ± 0.88 | 64.85 ± 1.95 | |
| 1.86 | ||||
|
| 10 | 96.37 ± 0.28 | – | – |
| 30 | 97.77 ± 0.27 | – | 50.53 ± 1.59 | |
| 3.68 | ||||
|
| 10 | – | – | 18.33 ± 0.42 |
| 30 | 30.45 ± 1.91 | 14.23 ± 2.75 | 72.05 ± 1.06 | |
|
| 10 | 97.71 ± 0.37 | 17.05 ± 2.37 | 18.06 ± 1.26 |
| 30 | 97.76 ± 0.23 | 29.26 ± 2.00 | 63.43 ± 0.98 | |
| 1.31 | ||||
|
| 10 | 96.80 ± 0.28 | – | – |
| 30 | 98.77 ± 0.24 | 10.25 ± 1.47 | – | |
| 4.17 | ||||
|
| 10 | 45.38 ± 1.57 | 14.23 ± 0.98 | – |
| 30 | 92.36 ± 0.23 | 29.48 ± 3.36 | 63.24 ± 2.54 | |
| 10.66 | ||||
|
| 10 | – | – | – |
| 30 | 10.45 ± 0.47 | 14.42 ± 1.48 | 72.73 ± 1.82 | |
|
| 10 | 75.15 ± 2.48 | – | – |
| 30 | 96.50 ± 0.32 | 28.69 ± 2.01 | 57.27 ± 2.58 | |
| 7.75 | ||||
| Cisplatin | 10 | 42.61 ± 2.33 | 88.64 ± 0.50 | 83.57 ± 1.21 |
| 30 | 99.93 ± 0.26 | 90.18 ± 7.78 | 95.02 ± 0.28 | |
| 12.43 | 7.84 | 1.30 | ||
* Growth inhibition values less than 10% were considered insignificant and the exact results are not given for simplicity.